- TV Footage
- Financial Reports
- Newsletter Overview
- Social Media
- Media Contact
Monheim, May 17, 2018 – Bayer is disappointed with the verdict of the General Court of the European Union’s on Case T-429/13 Bayer CropScience v European Commission. The Court has ruled that the European Commission’s decision from 2013, which restricted the use of certain neonicotinoids, was lawful. Bayer will review the verdict in detail and assess its consequences and potential legal options.
Bayer decided to pursue legal action to gain clarity on the legal basis of the Commission’s decision, which – in Bayer’s opinion – was uncertain. Bayer remains convinced of the safety of its products when applied in accordance with the label instructions.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2017, the Group employed around 99,800 people and had sales of EUR 35.0 billion. Capital expenditures amounted to EUR 2.4 billion, R&D expenses to EUR 4.5 billion. For more information, go to www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.